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AMPK b subunits contain a conserved domain that
causes associationwithglycogen. Althoughglycogen
availability is known to affect AMPK regulation in vivo,
the molecular mechanism for this has not been clear.
We now show that AMPK is inhibited by glycogen,
particularly preparationswith high branching content.
We synthesized a series of branched oligosaccha-
rides and show that those with a single a1/6 branch
are allosteric inhibitors that also inhibit phosphoryla-
tionbyupstreamkinases.Removal of theouter chains
of glycogen using phosphorylase, thus exposing the
outer branches, renders inhibition of AMPK more
potent. Inhibition by all carbohydrates tested was
dependent on the glycogen-binding domain being
abolished bymutation of residues required for carbo-
hydrate binding. Our results suggest the hypothesis
that AMPK, as well as monitoring immediate energy
availability by sensing AMP/ATP, may also be able
to sense the status of cellular energy reserves in the
form of glycogen.
INTRODUCTION
The AMPK-activated protein kinase (AMPK) is a regulator of
energy balance at both the single-cell and whole-body levels
(Kahn et al., 2005) and a target for drugs aimed at treatment of
type 2 diabetes and the metabolic syndrome (Hardie, 2007a).
AMPK is activated by metabolic stresses that inhibit ATP
synthesis or accelerate ATP consumption and is modulated by
cytokines regulating whole-body energy balance (Kahn et al.,
2005). Once activated, the system switches on catabolic path-
ways that generate ATP while switching off ATP-consuming
processes (Hardie, 2007b).
The native form of AMPK is a heterotrimeric complex
comprised of a catalytic a subunit and accessory b and g
subunits. The g subunits contain tandem domains that bind the
regulatory nucleotides AMP and ATP in a mutually exclusive
manner (Scott et al., 2004; Townley and Shapiro, 2007; Xiao
et al., 2007). By inhibiting dephosphorylation, binding of AMP
to the g subunit promotes net phosphorylation of the kinase
domain on the a subunit at a critical phosphorylation site in the
activation loop (Thr-172), causing > 100-fold activation (Hawleyet al., 1996; Suter et al., 2006). The phosphorylated kinase is
also allosterically activated by AMP, with both effects of AMP
being antagonized by high concentrations of ATP. Thr-172 is
phosphorylated in most cells by the tumor suppressor kinase
LKB1 (Hawley et al., 2003; Woods et al., 2003), but the effect
of AMP on phosphorylation is due to its ability to bind to AMPK
and render it a poorer substrate for protein phosphatases
(Davies et al., 1995; Suter et al., 2006; Sanders et al., 2007). In
some cell types (Hawley et al., 2005), Thr-172 can also be phos-
phorylated in a Ca2+-activated manner by calmodulin-depen-
dent protein kinases, especially CaMKKb.
In all eukaryotes, the b subunits contain a central conserved
region that we refer to as the glycogen-binding domain (GBD),
which causes AMPK complexes to associate with glycogen in
cultured cells and cell-free systems (Hudson et al., 2003; Pole-
khina et al., 2003). The Pfam database (http://pfam.sanger.ac.
uk/) identifies this as an N-isoamylase domain, a noncatalytic
domain mainly found in enzymes that metabolize the a1/6
linked branch points in starch and glycogen. The structure of
theGBD from rat AMPK-b1 has been determined in the presence
of b-cyclodextrin (Polekhina et al., 2005), an unbranched, cyclic
a1/4 linked oligosaccharide that does not occur naturally in
mammals.
There are many observations correlating glycogen content
with the regulation of AMPK, although the underlying molecular
mechanisms are poorly understood and there are paradoxes.
Prior glycogen loading of skeletal muscle suppresses activation
of AMPK by contraction or 5-aminoimidazole-4-carboxamide
(AICAR) in rodents (Derave et al., 2000; Wojtaszewski et al.,
2002) or exercise in humans (Wojtaszewski et al., 2003).
However, AMPK is hyperactivated by exercise in subjects with
McArdle disease (who are unable to mobilize glycogen due to
an inherited defect in glycogen phosphorylase) despite high
glycogen levels (Nielsen et al., 2002). Other paradoxes exist
when considering the role of AMPK in regulation of glycogen
synthesis. AMPK phosphorylates muscle glycogen synthase
(mGS) at site 2 (Ser-7) (Carling and Hardie, 1989). Phosphoryla-
tion at this site causes a decrease in activity at low concentra-
tions of the allosteric activator glucose-6-phosphate (Skurat
et al., 1994). Phosphorylation ofmGS at site 2 occurs in response
to AICAR treatment of muscle of wild-type mice, but not
AMPK-a2 knockoutmice, showing that this site is a physiological
target for AMPK (Jorgensen et al., 2004). Because AMPK is acti-
vated by exercise, one might expect mGS to be inactivated
following exercise. While this is indeed observed in humans
with McArdle disease (Nielsen et al., 2002), in normal subjects,Cell Metabolism 9, 23–34, January 7, 2009 ª2009 Elsevier Inc. 23
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vated after exercise, an effect that, in mice, requires the GM
glycogen-targeting subunit of protein phosphatase-1 (Aschen-
bach et al., 2001).
There are also interesting but unexplained connections
between muscle glycogen content, mGS activity, and insulin-
stimulated glucose uptake. Glycogen depletion by electrical
stimulation of mouse muscle was shown many years ago (Dan-
forth, 1965) to correlate with an increase in mGS activity indica-
tive of dephosphorylation. In rat muscle, glycogen content
appears to have a much greater influence on mGS activity than
insulin, with the effect of contraction on mGS being accounted
for entirely by glycogen depletion (Nielsen et al., 2001). In rats
(Richter et al., 1982) or humans (Mikines et al., 1988), insulin-
stimulated glucose uptake and glycogen synthesis is enhanced
following a single bout of exercise, and this correlates with the
degree of glycogen depletion (Richter et al., 2001).
In this paper, we report that glycogen inhibits purified AMPK in
cell-free assays, an effect that is dependent on binding to the
GBD and varies according to the branching content of the
glycogen. We show that oligosaccharides with single a1/6
branch points are allosteric inhibitors of AMPK that also inhibit
phosphorylation and activation by upstream kinases. Our results
suggest the concept that the GBD is a regulatory domain that
allows AMPK to act as a glycogen sensor in vivo.
RESULTS
Identification of Residues within the GBD Required
for Glycogen Binding
We first cloned DNA encoding the GBD of the rat AMPK-b1
subunit and expressed it in bacteria as a glutathione S-trans-
ferase (GST) fusion. The protein was purified on glutathione-
Sepharose to yield a polypeptide with the expected mass of
40 kDa (Figure S1A available online). To examine binding of
glycogen to this protein, we developed an assay using Sephar-
ose-bound concanavalin A (ConA), a plant lectin from jack bean
that binds glucans via the C3 and C4 hydroxyls of the glucose
monomers.Twodifferentpreparationsofglycogen,acommercial
preparation from bovine liver and one made in-house from rat
liver, were allowed to bind to ConA-Sepharose. These conju-
gates were then incubated with the GST:GBD fusion; recovered
by centrifugation; and the load, pellets, and supernatants
analyzed by SDS-PAGE. Figure 1A shows that the GST-GBD,
but not free GST, was recovered almost exclusively in the pellet
whenbovine liver glycogenwasused, indicating efficient binding.
The GBD appeared to bind less avidly to the rat liver glycogen,
because a larger proportion was found in the supernatant. By
contrast, muscle phosphorylase a, a protein with a well-defined
glycogen-binding site, was recovered almost exclusively in the
pellet with both glycogen preparations (Figure 1A).
Figure 1B shows an alignment of the GBD sequences from
b subunit isoforms of AMPK orthologs in a variety of different
eukaryotic species. A number of residues are conserved
throughout mammalian b subunits, including W100, K126,
W133, L146, and T148 (rat b1 numbering). The recent crystal
structure of the rat b1 GBD in complex with b-cyclodextrin sug-
gested that the side chains of all of these residues form direct
interactionswith theboundcarbohydrate, andmutationof several24 Cell Metabolism 9, 23–34, January 7, 2009 ª2009 Elsevier Inc.of themabolished glycogenbinding (Polekhina et al., 2003, 2005).
To confirm that these residues were involved with glycogen
binding, we mutated them to glycine or alanine and tested the
ability of the mutant GST-GBD protein to bind glycogen. As ex-
pected, all mutations markedly reduced binding of bovine liver
glycogen, as did a double-W100G/W133A mutation (Figure 1C).
Glycogen Preparations Inhibit Purified AMPK
with Different Potencies
We next tested the effect of glycogen on the activity of the native
AMPK complex purified from rat liver (Hawley et al., 1996).
Because they do not have defined structures, for all polysaccha-
rides studied, we express the concentrations in terms ofmoles of
glucose obtained after complete hydrolysis. The bovine liver
glycogen inhibited AMPK completely with an IC50 (concentration
causing half-maximal inhibition) of 30 ± 9 mM glucose equiva-
lents (Figure 2A). By contrast, rat liver glycogen had a much
less marked inhibitory effect, causing an extrapolated maximal
inhibition of only 44%, with an IC50 of 90 ± 16 mM. Although
most of the AMPK assays shown in this paper were performed
in the presence of 200 mM AMP, the bovine liver glycogen
inhibited both in the presence or absence of AMP (Figure 2B),
although the inhibition did appear to be somewhat more potent
in the presence of AMP.
We were concerned that the more marked inhibition observed
with bovine liver glycogen might have been due to the presence
of contaminants that inhibited AMPK, but this was not the case.
First, the glycogen did not inhibit a bacterially expressed GST
fusion of the rat AMPK-a1 kinase domain (data not shown).
Second, the inhibition did not occur (Figure 2C) with a recombi-
nant a1b1g1 complex expressed in human CCL13 cells that had
a truncation of residues 1–171 in the b1 subunit that removes the
GBD (Hudson et al., 2003). This experiment revealed two addi-
tional findings. First, the b subunit truncation reduced the total
activity of the complex measured in the absence of glycogen.
This has been observed previously (Hudson et al., 2003),
although the explanation remains unclear. Second, while the
concentration of glycogen used in Figure 2C (200 mM glucose
equivalents) produced 90% inhibition of purified native rat liver
AMPK (Figures 2A and 2B), inhibition of recombinant AMPK by
glycogen (or any of the other carbohydrates tested; see below)
was always < 50%. A key difference in the assay conditions
used for the native and recombinant AMPK (e.g., Figures 2A
and 2C) was that, while the former was performedwith the kinase
in solution, the latter was performed with the recombinant myc-
tagged kinase coupled to anti-myc antibodies, which was
necessary to remove it from the endogenous AMPK in the cells
used for expression. To test whether the reduced effect of
glycogen was caused by performing the assays in immunopre-
cipitates, we used rat liver AMPK (an approximately equal
mixture of a1b1g1 and a2b1g1 complexes) and assayed it either
in solution or in resuspended immunoprecipitates made using
anti-a1, anti-a2, or a mixture of anti-a1 and anti-a2 antibodies.
The results (Figure 2D) show that, when the assays were per-
formed in resuspended immunoprecipitates, the maximal inhibi-
tion by glycogen was only 30%–50%, as against > 95% when
the assays were performed in solution. Figure 2D also shows
that glycogen inhibits the a1b1g1 and a2b1g1 complexes puri-
fied from rat liver equally well.
Figure 1. Studies on Binding of Glycogen to Bacterially Expressed b1-GBD
(A) Binding of GST:GBD fusion, free GST, and phosphorylase a to glycogen. Samples of each protein were incubated with bovine or rat liver glycogen bound to
ConA-Sepharose, the Sepharose beads were recovered by centrifugation, and samples of the load (L), supernatant (S), and pellet (P, resuspended in the original
volume) were analyzed by SDS-PAGE.
(B) Alignment of GBD sequences from various eukaryotesmade using ALIGNX. Residues identical in all species are boxed, as are conserved residues inmamma-
lian species directly involved in carbohydrate binding; the latter are identified at the bottom (rat b1 numbering).
(C) Binding to glycogen of GST:GBD fusions (wild-type rat b1 or the point mutations shown). The binding assay was as in (A) using bovine liver glycogen, and
binding of phosphorylase a was analyzed as a positive control (bottom panel).
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itory potency of the preparations of bovine and rat liver glycogen
may have been due to differences in glycogen structure. Given
that the GBDs of the AMPK b subunits are related to domains
found in enzymes that metabolize a1/6 branch points, an
obvious possibility was that the differences were due to differing
contents of branching. To examine this, we used a method
involving enzymic hydrolysis of the branches followed by deter-
mination of the average chain length of the resulting linear a1/4
linked chains. This revealed that the bovine liver glycogen had an
average chain length of 13 ± 1 (mean ± SD, n = 3), whereas
the rat liver glycogen had an average chain length of 23 ± 3
(mean ± SD, n = 3), indicating a much lower average density of
branch points. To confirm this difference using another method,
we analyzed the absorption spectra of iodine complexes. The
complex between iodine and rat liver glycogen absorbed much
more strongly at higher wavelengths than that with the bovineliver glycogen, indicating a lower average degree of branching
(Figure 2E).
Effect of Point Mutations in the GBD on Inhibition
by Glycogen
To test whether mutations that interfered with the binding of
glycogen to the GBD also affected inhibition of AMPK by
glycogen, we made mutations in full-length b1 coexpressed
with a1 and g1 in CCL13 cells, isolated the complex by immuno-
precipitation via the myc tag on a1, and assayed the kinase
activity in the presence and absence of glycogen. The activities
were adjusted to correct for slight variation in recovery of the a1
subunit assessed by blotting (inset in Figure 3A). All mutations
that reduce glycogen binding to the isolated GBD (Figure 1C)
also abolished inhibition by bovine liver glycogen. A possible
exception was L146A, where some inhibition appeared to
remain, although inspection of Figure 1C suggests that this
mutation does not completely abolish glycogen binding either.
Because all of these assays were conducted in resuspended
immunoprecipitates, the degree of inhibition of the wild-type
was < 50%, as discussed in the previous section. As observed
already with the recombinant heterotrimer containing the trun-
cated b subunit (Figure 2C), all of the mutations except K126A
reduced the total activity in the absence of glycogen, albeit to
varying extents. This did not appear to be because the mutants
were less highly phosphorylated at Thr-172 than the wild-type.
In a separate experiment where wild-type b1, truncated b1
(172–270) lacking the GBD, or a W100G/W133A mutant were
coexpressed with a1 and g1, the phosphorylation of Thr-172
on a1 was identical (Figure 3B). This was the case whether the
cells were harvested by ‘‘rapid lysis’’ where the cells are lysed
in situ using ice-cold buffer containing detergent or ‘‘slow lysis’’
where the cells were harvested by trypsinization and centrifuga-
tion prior to lysis. The latter method causes increased phosphor-
ylation due to stresses occurring during cell harvesting. The lack
of inhibition by glycogen was also not because the mutant b1
Figure 2. Allosteric Inhibition of AMPK by
Different Glycogen Preparations
(A) Concentration dependence of inhibition of
native rat liver AMPK by preparations of bovine
and rat liver glycogen; glycogen concentrations
expressed as glucose produced after total hydro-
lysis. Data were fitted to an IC50 equation (see
Supplemental Experimental Procedures), and
curves were generated using the estimated best-
fit parameters.
(B) Concentration dependence of inhibition of
native rat liver AMPK by bovine liver glycogen in
the presence and absence of 200 mMAMP; curves
were generated as in (A).
(C) Inhibition by bovine liver glycogen of recombi-
nant AMPK complex (myc-a1:b1:g1) containing
full-length (1–270) or truncated b1 subunit lacking
the GBD (172–270). Complexes were expressed in
CCL13 cells and purified by immunoprecipitation
prior to assay with or without glycogen (200 mM
glucose equivalents). Data are means ± SEM
(n = 3). *Activity different from control without
glycogen by t test (p < 0.05).
(D) Inhibition by bovine liver glycogen (200 mM
glucose equivalents) of purified, native rat liver
AMPK (a mixture of a1b1g1 and a2b1g1
complexes) that had been recovered by immuno-
precipitation (IP) using anti-a1, anti-a2, or amixture
of anti-a1/-a2 antibodies or assayed in solution
without immunoprecipitation. Results are ex-
pressed as percentages of the activity in controls
without glycogen, anddata aremean±SEM (n=3).
(E) Absorption spectra of bovine and rat liver
glycogen preparations in complex with iodine.
subunits failed to form complexes with
a1 and g1. The W100G/W133A double
mutant b1 was recovered in approxi-
mately equal amounts with a1 and g1
whether immunoprecipitated via the myc
epitope on a1 or via the FLAG epitope
on g1 (Figure 3C).
To test whether binding of glycogen to the GBD caused inhibi-
tion of AMPK complexes containing the b2 rather than the b1
isoform, we expressed complexes containing rat a1 and g1
with human b2, with or without mutation of the two tryptophan
residues equivalent to W100 and W133 in b1 (W99G/W133A).
The results were very similar to those for b1 in that the wild-
type complex was inhibited by glycogenwhile the double-trypto-
phan mutation, which reduced the total activity by 70%,
also completely abolished the inhibitory effect of glycogen
(Figure 3D).
A Cyclic a1/4 Linked Oligosaccharide Inhibits AMPK,
but Linear Oligosaccharides Do Not
The different results obtained with bovine and rat liver glycogen
illustrate a major problem in studying glycogen as a regulatory
molecule, in that the polysaccharide does not have a defined
structure and varies in both size and degree of branching. Pole-
khina et al. (2003, 2005) have previously shown that b-cyclodex-
trin, a cyclic a1/4 linked oligosaccharide of seven glucose
Cell Metabolism
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Figure 3. Effect of b Subunit Mutations on Inhibition of Recombinant
AMPK Complexes by Glycogen
(A)Myc-a1, g1, and b1 with the wild-type sequence or the indicated mutations
were expressed in CCL13 cells, immunoprecipitated, and assayed ± bovine
liver glycogen (200 mM glucose equivalents); results are mean ± SEM (n = 3).
The lower panel shows expression of the a1 subunit assessed by probing blots
using anti-myc antibody; the activities in the upper panel were corrected for
small variations in expression.
(B) Myc-a1, g1, and either wild-type b1, a W100G/W133A mutant, or an
N-terminally truncated mutant (b1 172–270) were expressed in CCL13 cells,
extracted using the rapid or slow lysis procedures, and subject towestern blot-
ting using anti-myc or anti-pT172 antibodies.
(C) Myc-a1, g1, and b1 with the wild-type sequence or with W100G/W133A
mutations were expressed in CCL13 cells, immunoprecipitated using anti-
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Therefore, we tested whether b-cyclodextrin also caused inhibi-
tion. Figure 4A shows that this was indeed the case with a half-
maximal effect at 1.6 mM, which is close to the KD of 0.3 mM
measured for binding of b-cyclodextrin to the bacterially ex-
pressed rat b1 GBD by Koay et al. (2007). This inhibition was
dependent on binding to the GBD because it was abolished by
the double-tryptophan mutation (W100G/W133A) in b1
(Figure 4B).
Polekhina et al. (2005) also found that linear a1/4 linked
oligosaccharides with more than five glucose units, i.e., malto-
hexaose and maltoheptaose, could displace the b1 GBD from
glycogen at concentrations greater than 1 mM. Maltoheptaose
is equivalent to b-cyclodextrin but with a break in the chain so
that it has free reducing and nonreducing ends. Surprisingly,
these linear oligosaccharides produced almost no inhibition of
native rat liver AMPK even at concentrations up to 100 mM
(Figures 4C and 4D), although we did confirm that they could
bind the GBD (data not shown). Using an NMR method, Koay
et al. (2007) estimated KD values of 0.7 and 0.4 mM for binding
of maltohexaose and maltoheptaose to the bacterially ex-
pressed rat b1 GBD. Thus, these linear oligosaccharides do
not inhibit AMPK even at concentrations where binding should
be saturated.
Isolation of a Fragment of Glycogen that Binds
to the GBD and Inhibits AMPK
In an attempt to establish the chemical nature of the regions of
glycogen that bind to the GBD and cause inhibition of the
AMPK complex, we carried out partial acid hydrolysis of bovine
liver glycogen and utilized the b1 GBD as an affinity matrix to
purify hydrolysis products that bound to the GBD. The hydrolysis
conditions were chosen to yield a range of oligosaccharides con-
taining up to six glucose units, as detected by high-performance
anion exchange chromatography (HPAEC). The hydrolysate was
passed down a glutathione Sepharose column to which the
GST-GBD had been prebound, and bound oligosaccharides
eluted with propionic acid. The eluted oligosaccharides were
analyzed by HPAEC (Figure 5A). A large peak at 1.7 min was
shown to be an artifact caused by propionic acid, while three
peaks at 3.5, 5.0, and 6.5 min were analyzed by electrospray
ionization-mass spectrometry. The peaks at 3.5 and 6.5 min
did not appear to contain carbohydrate, but the peak at 5 min
yielded a mass of 365, consistent with a disaccharide. That
this disaccharide contained glucose was confirmed by colli-
sion-induced dissociation and tandem mass spectrometry
(Figure 5B); the product ion spectrum contained a daughter
peak at 203, corresponding to the mass of glucose plus one
Na+ ion. The only disaccharides expected from partial acid
myc (left) or anti-FLAG (right) antibodies, and analyzed by western blotting
using anti-myc antibodies (top panels) or a mixture of anti-b1 and -g1 anti-
bodies (bottom panels).
(D) Myc-a1, g1, and human b2 with the wild-type sequence or with W99G/
W133A mutations were coexpressed, immunoprecipitated, and assayed ±
bovine liver glycogen (200 mM glucose equivalents); results are mean ±
SEM (n = 3). Activities were corrected for small variations in the observed level
of expression as in (A). *Activity different from control without glycogen by t test
(p < 0.05).
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hydrolysis of glycogen are maltose (a1/4 linked) and isomal-
tose (a1/6 linked). Attempts to identify the disaccharide by
chemical linkage analysis were not successful. However, an
isomaltose standard was found to elute from the HPAEC column
at 5.1 min, whereas maltose eluted at 10.1 min. These results
suggested that the disaccharide that was derived from glycogen
and that bound to the b1-GBD was isomaltose.
Interestingly, isomaltose inhibited native rat liver AMPK with
a half-maximal effect at 16 mM, whereas maltose did not cause
any inhibition at concentrations up to 100 mM (Figure 5C). As
with bovine liver glycogen, isomaltose did not inhibit a T172D
mutant of the a1 kinase domain expressed in bacteria (data
not shown). As observed with other inhibitory glucans, isomal-
tose inhibited wild-type recombinant a1b1g1 complexes, but
not complexes containing a double-tryptophan mutation in b1
(Figure 5D).
Effect of Synthetic Branched Oligosaccharides
on AMPK Activity
To test whether oligosaccharides larger than isomaltose with an
a1/6 linkage would be more potent inhibitors, we chemically
synthesized a series of a1/4 linked oligosaccharides, contain-
ing from three to six glucose units, with a single a1/6 linkage
(Figure 6A). Because oligosaccharides with a free reducing end
exist in solution as mixtures of a and b anomers, these oligosac-
charides were synthesized with a methoxy group at carbon 1 of
the glucose at the reducing end, in the a configuration. For
comparison, we also synthesizedmethyl a-maltoside andmethyl
a-isomaltoside.
These oligosaccharides were tested for their ability to inhibit
AMPK (Figure 6B; the structures and estimated IC50 values are
shown in Figure 6A). Surprisingly, whereas maltose with a free
reducing group did not inhibit AMPK, methyl a-maltoside did
inhibit, with an IC50 of 1.7 mM. Inhibition was also more potent
with methyl a-isomaltoside (IC50 = 0.6 mM) than with isomaltose
Figure 4. Effect of Unbranched Oligosaccharides
on AMPK Activity
(A) Inhibition of native rat liver AMPK by b-cyclodextrin.
The curve was generated as in Figure 2A.
(B) Effect of GBD double mutation on inhibition of
recombinant AMPK by 2 mM b-cyclodextrin. Myc-a1,
g1, and b1 with the wild-type sequence or with W100G/
W133A mutations were coexpressed, immunoprecipi-
tated, and assayed ± b-cyclodextrin (2 mM). The activities
were corrected for small variations in the observed level of
expression as in Figure 2A. *Activity different from control
without b-cyclodextrin (p < 0.05).
(C and D) Effect of maltohexaose (C) and maltoheptaose
(D) on AMPK activity. Native rat liver AMPK was assayed
in the presence and absence of the indicated concentra-
tions of oligosaccharide. Results in (B) through (D) are
mean ± SEM (n = 3).
(IC50 = 16 mM). Intriguingly, a1/4 linked
glucose oligosaccharides containing from three
to six glucose units and a single a1/6 linkage
were more potent inhibitors, all with IC50 values
of less than 0.5 mM. The most potent was
a trisaccharide containing two glucose units
on the secondary (branch) chain and a single a-methyl glucoside
on the primary chain (Glca1/4Glca1/6Glca-OMe), which had
an IC50 of 90 mM.
To confirm that the inhibition by these oligosaccharides was
dependent on binding to the GBD, we tested their effects on
recombinant a1b1g1 complexes expressed in CCL13 cells. As
expected, they all inhibited wild-type AMPK, although, at the
single concentration used (2 mM), the inhibition by methyl
a-maltoside was not significant. However, none of them inhibited
recombinant complexes containing the double-W100G/W133A
mutation in b1 (Figure 6C). As observed in other experiments,
there was a decrease of about 70% in the activity of the double
mutant in the absence of oligosaccharide.
Effect of Branched Oligosaccharides
on Phosphorylation/Dephosphorylation of AMPK
The inhibitory effects observed to this point represent allosteric
inhibition, i.e., direct effects on the activity of the AMPK kinase
domain of carbohydrate binding at a different site, i.e., the GBD
on the b subunit. It was important to establish whether carbohy-
drates might also affect phosphorylation and dephosphorylation
byupstreamkinases andphosphatases. Figures 7Aand7Bshow
that the most potent inhibitory branched oligosaccharide
(Glca1/4Glca1/6Glca-OMe) had no significant effect on
dephosphorylation of purified rat liver AMPKbyprotein phospha-
tase-2Ca (PPM1A). Similar negative results were obtained using
the catalytic subunit of protein phosphatase-1 (data not shown).
However, the trisaccharide did cause a marked inhibition of
phosphorylation of Thr-172 by CaMKKb (Figures 7C and 7D)
and LKB1 (Figure 7E). To confirm that the latter was not an effect
on LKB1, we tested the effect of the oligosaccharide on phos-
phorylation of a synthetic peptide substrate, i.e., LKBtide (Liz-
cano et al., 2004). There was no significant inhibition at 1 mM
oligosaccharide (Figure 7F), when inhibition of phosphorylation
of the rat liver abg complex was essentially complete (Figure 7E).
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Increased Inhibition by a Phosphorylase Limit Dextrin
Neither isomaltosenor anyof the synthetic branchedoligosaccha-
rides are likely to occur naturally in vivo, although they can be
considered as mimics of the branch points in glycogen. To
examine the effects of the branch points in glycogen itself, we
studied the effects of phosphorylase digestion. Phosphorylase
degrades the outer chains of glycogen sequentially by phospho-
rolysis but stops when close to the branch points (Walker and
Whelan,1960).Wereasoned that, ifwedigestedglycogenexhaus-
tively with phosphorylase in the absence of debranching enzyme,
wewould generate a limit dextrin inwhich the branchpointswould
be exposed on the surface. By contrast, in undigested glycogen,
the branch points would be buried beneath the outer chains and
may be less accessible to AMPK. Our prediction was that the limit
dextrin would be amore potent inhibitor than the parent glycogen.
During initial trials of this approach, we found that commercial
preparations of phosphorylase are contaminatedwith debranch-
Figure 5. Isolation of Isomaltose as an Inhibitor of
AMPK
(A) Bovine liver glycogen was subjected to partial acid
hydrolysis and the hydrolysate passed through a gluta-
thione Sepharose column to which the GST:GBD fusion
had been prebound. The column was eluted with pro-
pionic acid and bound oligosaccharides analyzed by
HPAEC. The peak eluting at 5 min was the only one found
to contain carbohydrate.
(B) Analysis of the peak eluting at 5 min by tandem ES-MS
using collision-induced dissociation. Oligosaccharide
fragments are observed as adducts with Na+ ions,
increasing their mass by 23.
(C) Effect ofmaltose and isomaltose on AMPK activity. The
curve for isomaltose was generated using the best-fit
parameters as in Figure 2A.
(D) Effect of GBD double mutation on inhibition of
recombinant AMPK by 20 mM isomaltose; results are
mean ± SEM (n = 3). *Activity different from control without
isomaltose by t test (p < 0.05).
ing enzyme, which had to be removed by further
purification. Using highly purified phosphory-
lase, the release of glucose as glucose-1-phos-
phate from bovine liver glycogen reached
a plateau corresponding to 28% release of the
total glucose in the glycogen. This is the ex-
pected amount because about 30% of the
glucose in an undegraded glycogen molecule
is expected to be in the outer tier, irrespective
of the number of tiers (Melendez-Hevia et al.,
1993). To prepare the limit dextrin, we incu-
bated the glycogen with the cosubstrate phos-
phate with or without phosphorylase and also
kept a sample of the untreated parent glycogen.
Since the removal of the unbranched outer
chains by phosphorylase treatment would
increase the average degree of branching, this
was assessed by measuring the absorption
spectrum of the complex between the polysac-
charide product and iodine. The lmax values of
the complexes with untreated glycogen, mock-
treated glycogen, and phosphorylase-treated glycogen were
397, 372, and 350 nm, respectively. This indicates that, while
the phosphorylase treatment did remove the outer branches
and, thus, increase the average degree of branching, there
was also some increase in branching content in the mock-
treated sample, presumably because of trace contamination of
the commercial preparation of bovine liver glycogen with active
phosphorylase.
As predicted (Figure 7G), the phosphorylase treatment
increased the potency of inhibition of rat liver AMPK, with the
IC50 decreasing from 38 to 5 mM (glucose equivalents). The
mock-treated sample yielded inhibition of intermediate potency
(IC50 = 21 mM), consistent with the idea that some phosphorol-
ysis may have occurred. As with other inhibitory carbohydrates,
the inhibition of a recombinant a1b1g1 complex by the phos-
phorylase-treated limit dextrin was abolished by the W100G/
W133A mutation (Figure 7H).
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DISCUSSION
The results in this paper reveal that the glycogen-binding domain
on the b subunits of AMPK, rather than just localizing AMPK on
glycogen, is also a regulatory domain that allosterically inhibits
the kinase activity (and inhibits phosphorylation by upstream
kinases) when glycogen is bound, thus allowing AMPK to act
as a glycogen sensor. We were initially concerned that inhibition
of AMPK by the commercial bovine liver glycogen might be
explained by contamination with molecules that interfered in
the assay. However, the glycogen preparation did not inhibit
the isolated AMPK-a1 kinase domain, showing that it was not
Figure 6. Inhibition of Rat Liver AMPK by Synthetic
Branched Oligosaccharides
(A) Table showing the identification (ID) number, structure,
and estimated IC50 ± SEM.
(B) Inhibition of purified rat liver AMPK by oligosaccha-
rides. These data were used to generate the IC50 values
shown in (A), and the curves were drawn using the best-
fit parameters. A key to the ID of each oligosaccharide is
shown on the right.
(C) Inhibition of recombinant wild-type and W100G/
W133A mutant AMPK (a1b1g1 complex) by synthetic
oligosaccharides, numbered as in (A) and (B). The data
are presented with the oligosaccharides in order of
increasing potency from left to right; results are mean ±
SEM (n = 3). Significant differences ± oligosaccharide for
the wild-type by two-way ANOVA. *p < 0.05; ***p < 0.001.
a nonspecific inhibitor of the catalytic activity.
Moreover, inhibition was dependent on binding
of glycogen to the GBD, because it was not
observed with recombinant a1b1g1 complexes
containing a truncated b subunit lacking the
domain or containing point mutations in the
b subunit that disrupt glycogen binding.
A major problem with the study of glycogen
as a regulatory molecule is that it does not
have a defined structure, so different prepara-
tions may behave quite differently. This is illus-
trated by the dramatic difference in inhibitory
effect between the preparations of bovine and
rat liver glycogen. This may also account for
the findings of Polekhina et al. (2003), who
reported that glycogen did not inhibit purified
rat liver AMPK, and for the failure of Parker
et al. (2007) to find any AMPK associated with
glycogen purified from rat liver. Parker et al.
(2007) purified glycogen using a procedure
involving sucrose gradient centrifugation and
size exclusion chromatography, and another
possibility is that AMPK dissociated during this
procedure.
A consistent finding throughout this study
was that, while native rat liver AMPK (a mixture
of the a1b1g1 and a2b1g1 complexes [Woods
et al., 1996]) was completely inhibited by bovine
liver glycogen and branched oligosaccharides,
recombinant AMPK complexes expressed in
human cells and assayed in immunoprecipitates were inhibited
to a much lower extent, usually only by 30%–50%. However,
this was due to carrying out the assays in immunoprecipitates
rather than in solution, because a similar incomplete degree of
inhibition was obtained in resuspended immunoprecipitates
obtained from preparations of native rat liver AMPK using anti-a1
or -a2 antibodies. These experiments also revealed that native
complexes from rat liver containing either the a1 or the a2
isoform were both susceptible to inhibition by glycogen.
Why did the preparations of bovine and rat liver glycogen differ
markedly in their ability to inhibit AMPK? We suspected that this
might be due to different degrees of branching. In support of this,
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the average branching content of the rat liver glycogen was
found to be much less than that of the bovine liver glycogen,
a result confirmed by examining the absorption spectra of the
iodine complexes. Most published estimates of the average
chain length of mammalian glycogen suggest that it lies between
12 and 18 glucose units (Illingworth et al., 1952), in line with our
value of 13 ± 1 for bovine liver glycogen but making our value of
23 ± 3 for the rat liver glycogen seem high. However, the latter
was not purified by the traditional extraction in hot alkali but by
a method designed for purification of glycogenin involving
successive extractions with cold trichloroacetic acid, LiBr, and
SDS (Smythe et al., 1989). It is possible that these two methods
select out subfractions of glycogen with different degrees of
branching.
The idea that it is the branch points in glycogen that bind with
high affinity to the GBD and cause inhibition of AMPK was sup-
ported by our findings that, following partial acid hydrolysis of
Figure 7. Effect of Oligosaccharide Number 5, See
Figure 6, on Dephosphorylation of AMPKby PP2Ca
and on Phosphorylation by CaMKKb and LKB1
(A) Effect of oligosaccharide on dephosphorylation by
PP2Ca. Rat liver AMPK was incubated with PP2Ca in
the presence and absence of 1 mM oligosaccharide; at
various times, levels of total a subunit and phosphorylation
on Thr-172 were assessed by western blotting.
(B) Quantification of results as in (A); means ± SEM of two
experiments.
(C) Effect of oligosaccharide on phosphorylation by
CaMKKb. Rat liver AMPK was dephosphorylated using
PP1, okadaic acid was added to inhibit the phosphatase,
and the protein was incubated with MgATP and CaMKKb
in the presence and absence of 1 mM oligosaccharide. At
various times, levels of total a subunit and of phosphoryla-
tion on Thr-172 were assessed by western blotting.
(D) Quantification of results as in (C); means ± SEM (n = 2).
(E) Time course of effect of oligosaccharide on phosphor-
ylation by LKB1, performed as in (C) but with LKB1 in place
of CaMKKb.
(F) Effect of oligosaccharide on phosphorylation of
a synthetic peptide substrate of LKB1 (mean ± SD; n = 2).
(G) Inhibition of AMPK by bovine liver glycogen, a phos-
phorylase limit dextrin, and a mock-treated sample. IC50
values were determined as in Figure 2A and curves gener-
ated from the best-fit parameters.
(H) Effect of limit dextrin on recombinant a1b1g1 complex
with wild-type and W100G/W133A mutant b1. Results are
mean ± SEM (n = 3). *Activity different from control without
limit dextrin (p < 0.05).
bovine liver glycogen, isomaltose was recov-
ered by binding to the immobilized b1 GBD. Iso-
maltose was found to inhibit AMPK, whereas
maltose did not. We also found that maltohex-
aose and maltoheptaose (containing six and
seven glucose units all a1/4 linked) did not
inhibit AMPK significantly, although they do
bind to the GBD (Koay et al., 2007).
Maltose, isomaltose, maltohexaose, andmal-
toheptaose all have a free reducing end that can
interconvert via the open chain form to give
a mixture of a- and b-anomers, although the
b-anomer is thought to predominate. We synthesized derivatives
of maltose and isomaltose with an a-methoxy group at C1 of the
reducing end and found that (unlike maltose itself) methyl a-mal-
toside did inhibit AMPK, while methyl a-isomaltoside was
a much more potent inhibitor than isomaltose. In addition,
b-cyclodextrin (a cyclized form of maltoheptaose that lacks
a free reducing end) inhibited AMPK, whereas maltoheptaose
did not. These results suggest that the presence of a free
reducing end somehow abolishes the inhibition of AMPK by
oligosaccharides, possibly due to the presence of the b-anomer.
Although the molecular explanation for this phenomenon
remains unclear, polysaccharides or oligosaccharides with free
reducing ends are unlikely to occur in vivo.
We suspected that the true physiological ligands for the GBDs
of AMPK might be the branch points in glycogen, which isomal-
tose was mimicking. To generate better models for such branch
points, we synthesized a series of oligosaccharides containing
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from three to six a1/4 linked glucose units with a single a1/6
linkage and an a-methoxy group at the reducing end. These
small, branched oligosaccharides were more potent inhibitors
of AMPK than methyl a-isomaltoside. The most potent was
a trisaccharide (Glca1/4Glca1/6Glca-OMe) with two glucose
units on the branched side chain, which had an IC50 9-fold lower
thanmethyl a-isomaltoside and almost 20-fold lower thanmethyl
a-maltoside. This may represent the smallest ligand that makes
all possible favorable contacts with the binding site on the GBD.
A molecule of glycogen is thought to have a theoretical
maximum of 12 tiers of branching, because, above this limit,
the outer chains may become so tightly packed that no further
branching can be accommodated (Melendez-Hevia et al.,
1993). If this view of glycogen structure is correct, it would imply
that AMPKwould only be able to bind to the nonreducing ends at
the surface of a full-size glycogen molecule and may not be able
to gain access to internal branch points. However, as phosphor-
ylase degrades the outer chains of glycogen, it would expose the
outer tier of branch points. Phosphorylase stops degrading the
outer chains when four glucose units remain on the side chain
(Walker and Whelan, 1960) and cannot proceed further until
the branches are resolved by debranching enzyme. Therefore,
we suspected that a limit dextrin made by exhaustive digestion
of bovine liver glycogen with phosphorylase might be a more
potent inhibitor of AMPK than the parent glycogen. This was,
indeed, the case (Figure 7G). Thus, removal of the outer chains
of glycogen by phosphorylase markedly increases the potency
of inhibition of AMPK.
Our results confirm the idea that the GBDs of the AMPK
b subunits represent a regulatory domain that inhibits the kinase
activity and suggest that branch points within glycogen are the
true inhibitory ligands. Although much further work is required
to establish the physiological role of this phenomenon, we
suggest the following working hypothesis. We propose that
a significant proportion of AMPK, especially inmuscle containing
a high glycogen content, may be bound to the nonreducing ends
at the surface of glycogen, partially sequestering AMPK away
from other downstream targets. This could account for the
reduced apparent activation of AMPK in response to AICAR
(Wojtaszewski et al., 2002) or contraction (Derave et al., 2000;
Wojtaszewski et al., 2003) when muscle is in a glycogen-loaded
state. However, because the densely packed outer chains may
prevent access to most of the internal branch points, AMPK
bound to glycogen under these conditions would not be in an in-
hibited state and would phosphorylate mGS at site 2, providing
a feedback inhibition of the further extension of the outer
glycogen chains. If muscle contraction then commenced and
phosphorylase was activated, it would expose the outermost
tier of branch points (assuming that debranching enzyme did
not immediately resolve them), which would now inhibit AMPK.
AMPK would no longer phosphorylate mGS, allowing the latter
to become dephosphorylated and activated, paving the way
for rapid glycogen resynthesis once contraction ceased.
Our hypothesis can explain many of the observations and
paradoxes discussed in the Introduction. For example, it can
explain why mGS is less active due to phosphorylation at site 2
in glycogen-loaded muscle (Jorgensen et al., 2004; Lai et al.,
2007). It also explains why, following glycogen depletion caused
by electrical stimulation in rat muscle (Danforth, 1965; Nielsen32 Cell Metabolism 9, 23–34, January 7, 2009 ª2009 Elsevier Inc.et al., 2001) or exercise in human muscle (Wojtaszewski et al.,
2001), mGS is found to be in an active, dephosphorylated state.
The AMPK bound to glycogen would be inhibited under these
conditions, allowing net dephosphorylation of mGS by the
glycogen-bound form of protein phosphate-1 (Aschenbach
et al., 2001).
As well as causing allosteric inhibition, the trisaccharide
Glca1/4Glca1/6Glca-methyl inhibited phosphorylation by
upstream kinases, but not dephosphorylation by PP2Ca or
protein phosphatase-1. This contrasts with the effect of the
well-established allosteric activator of AMPK, i.e., AMP, which
inhibits dephosphorylation without affecting phosphorylation
(Davies et al., 1995; Suter et al., 2006; Sanders et al., 2007). Inhi-
bition of Thr-172 phosphorylation by glycogen may account for
findings that AMPK is more highly phosphorylated at this site
in rat muscle that has a low glycogen content (Jorgensen
et al., 2004). However, it seems likely that the level of Thr-172
phosphorylation would rapidly revert to normal once AMPK
had dissociated from glycogen, i.e., that the inhibitory effect of
glycogen would only be experienced by those AMPK targets
that are resident in the glycogen particle, like mGS.
Our hypothesis may also help to explain the increase in insulin-
stimulated glucose uptake following a single bout of exercise
(Richter et al., 1982; Mikines et al., 1988), which correlates with
the extent of glycogen depletion (Richter et al., 2001). Removal
of the outer tier of glycogen by phosphorylase releases about
30% of the available glucose and halves the number of nonre-
ducing ends (Melendez-Hevia et al., 1993). Thus, even a modest
reduction in glycogen content might cause release of significant
quantities of AMPK from the polysaccharide so that more of the
kinase becomes available to phosphorylate targets involved in
glucose uptake and/or insulin signaling.
In conclusion, our results suggest the hypothesis that the
AMPK complex can sense not only the immediate availability
of cellular energy in the form of AMP and ATP but also the avail-
ability of medium-term energy reserves in the form of glycogen.
EXPERIMENTAL PROCEDURES
Experimental procedures used in this study are presented in the Supplemental
Data.
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